Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia

Tropical Medicine and International Health

Volumn 10, Issue 2, 2005, Pages 139-145

  Depoortere, Evelyn ^a   Guthmann, Jean Paul ^a   Pressé, Jacinthe ^b   Sipilanyambe, Naawa ^c   Nkandu, Esther ^d   Balkan, Suna ^b   De Pécoulas, Philippe Eldin ^e   Legros, Dominique ^a  

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c National Malaria Control Centre   (Zambia)

^d UNIVERSITY OF ZAMBIA   (Zambia)

^e CHU CÔTE DE NACRE   (France)

Author keywords

Artemisinin based combination therapy; Effectiveness; Efficacy; Malaria; Plasmodium falciparum; Refugee settlement; Zambia

Indexed keywords

ARTEMETHER; ARTESUNATE; FANSIDAR; QUININE;

DISEASE TREATMENT; DRUG PRESCRIBING; MALARIA; REFUGEE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MONITORING; DRUG RESISTANCE; FEMALE; FOLLOW UP; GAMETOCYTE; GENETIC MARKER; HUMAN; INFANT; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MONOTHERAPY; PARASITEMIA; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REFUGEE; REINFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; ZAMBIA;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENETIC MARKERS; GENOMICS; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PATIENT COMPLIANCE; PYRIMETHAMINE; REFUGEES; SESQUITERPENES; SULFADOXINE; TREATMENT OUTCOME; ZAMBIA;

AFRICA; EASTERN HEMISPHERE; SOUTHERN AFRICA; SUB-SAHARAN AFRICA; WORLD; ZAMBIA;

ARTESUNATE; CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 13944273060     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2004.01363.x     Document Type: Article

References (19)

1. Bijl HM, Kager J, Koetsier DW & van der Werf TS (2000) Chloroquine- and sulfadoxine-pyrimethamine resistant falciparum malaria in vivo - a pilot study in rural Zambia. Tropical Medicine and International Health 5, 692-695.
2. Bloland PB (2001) Drug Resistance in Malaria. World Health Organization, Geneva.
3. Contamin H, Fandeur T, Bonnefoy S, Skouri F, Ntoumi F & Mercereau-Puijalon O (1995) PCR typing of field isolates of Plasmodium falciparum. Journal of Clinical Microbiology 33, 944-951.
4. Depoortere E, Guthmann J-P, Sipilanyambe N et al. (2004) Adherence to the combination of sulfadoxine-pyrimethamine and artesunate in the Maheba Refugee Settlement, Zambia. Tropical Medicine and International Health 9, 62-67.
5. Guerin PJ, Olliaro P, Nosten F et al. (2002) Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infectious Diseases 2, 564-573.
6. International Artemisinin Study Group (2004) Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363, 9-17.
7. Kublin JG, Dzinjalamala FK, Kamwendo DD et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Journal of Infectious Diseases 185, 380-388.
8. National Malaria Control Centre (Compiled by) (2000) Drug Sensitivity Study Summary Report. October 1999-February 2000. National Malaria Control Centre, Lusaka, Zambia.
9. Nosten F & Brasseur P (2002) Combination therapy for malaria. The way forward? Drugs 62, 1315-1329.
10. Omar SA, Adagu IS & Warhurst DC (2001) Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 315-319.
11. Peterson DS, Walliker D & Wellems TE (1988) Evidence that a point mutation in dihydrofolate-reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proceedings of the National Academy of Sciences of the United States of America 85, 9114-9118.
12. Trape JF (2001) The public health impact of chloroquine resistance in Africa. American Journal of Tropical Medicine and Hygiene 64, 12-17.
13. Vasconcelos KF, Plowe CV, Fontes CJ et al. (2000) Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Memorias do Instituto Oswaldo Cruz 95, 721-728.
14. Von Seidlein L, Milligan P, Pinder M et al. (2000) Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 355, 352-357.
15. White NJ (1999) Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41, 301-308.
16. White NJ & Olliaro PL (1996) Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitology Today 12, 399-401.
17. White NJ, Nosten F, Looareesuwan S et al. (1999) Averting a malaria disaster. Lancet 353, 1965-1967.
18. World Health Organisation (WHO) (1996) Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Falciparum Malaria in Areas with Intense Transmission. WHO/ MAL/96.1077.
19. World Health Organisation (WHO) (2002) Monitoring Antimalarial Drug Resistance. Report of a WHO Consultation. World Health Organisation, Geneva, Switzerland. 3-5 December 2001. WHO/CDS/CSR/EPH/2002.17.